Overview

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

Status:
Completed
Trial end date:
2017-12-22
Target enrollment:
Participant gender:
Summary
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
Phase:
Phase 2
Details
Lead Sponsor:
Almirall, S.A.
Kinex Pharmaceuticals Inc
Collaborator:
Athenex, Inc.
Treatments:
Tirbanibulin